Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18-75 years who satisfied RomeIII criteria for the diagnosis of IBS~* Signed informed consent~Exclusion Criteria:~* IBS-D~* evidence of cathartic colon or history laxative abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Probiotics(Medirac) 10/mosapride 10mg (Type: EXPERIMENTAL): None
- Probiotics(Medirac) 15/mosapride 10mg (Type: EXPERIMENTAL): None
- Probiotics(Medirac) 15/mosapride 15mg (Type: EXPERIMENTAL): None
- Probiotics(Medirac) 30/mosapride 15mg (Type: EXPERIMENTAL): None
- Probiotics(Medirac) placebo/mosapride placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).